Clinical trial registry record

Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 4 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated April 11, 2012.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT00129961
Last registry update
April 11, 2012
Status
Completed
Phase
Phase 4
Sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Enrollment
86
Countries
United States, Australia, Canada, New Zealand
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 4
Study design
RANDOMIZED · PARALLEL · PREVENTION · NONE
Evidence population
Human clinical study registration
Participants
86
Population
ALL · 18 Years
Duration
2005-08-01 to 2009-01-01
Intervention
sirolimus; cyclosporine or tacrolimus
Comparator
2
Outcomes measured
New Biopsy-Confirmed Nonmelanoma Skin Cancer (NMSC) Lesions Per Subject Per Year — up to 24 months; Time to First Biopsy Confirmed New NMSC Lesion. — up to 24 months; Number of Lesion Free Subjects — up to 24 months; Percentage of Patients With New Biopsy-confirmed NMSC: Squamous Cell Carcinoma (SCC) and Basal Cell Carcinoma (BCC) — u…; Grade Distribution of NMSC Lesions — up to 24 months; Number of Recurrent NMSC Lesions Per Subject-year — up to 24 months; Subjects Reporting Incidence of Metastatic Disease Related to NMSC. — up to 24 months; Death Due to NMSC — up to 24 months; Number of Subjects Who Discontinue Assigned Therapy — up to 24 months; Nankivell-Calculated Glomerular Filtration Rate (GFR) — At 24 months (week 104); Serum Creatinine Level — At 24 months (Week 104); Number of Participants That Died — up to 24 months; Graft Survival Measured by Graft Loss — up to 24 months; Number of Subjects With Biopsy-Confirmed Acute Rejection — up to 24 months; Spot Urine Protein:Creatinine Ratio — At 24 months (Week 104)
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 4A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Rapamycin · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Source terminology contains a controlled topic term.

Automated source check 100% · update recency 35%. These figures help sort records; they are not medical ratings.

rapamycin
Read the original source →Export JSON